PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone
SZ5202
Approved small_molecule active
Quick answer
PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone for Multiple Myeloma is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Multiple Myeloma
- Phase
- Approved
- Modality
- small_molecule
- Status
- active